Indeed, our results are agreed with Corremans R, et al., who demonstrated the equally renoprotective effects of metformin and canagliflozin, a SGLT-2 inhibitor, in diabetic CKD rat models [31]. Here, SLC5A2 is linked to chronic kidney disease.